$ABEO

Silverstein Christine Berni sold $104K of ABEO

Silverstein Christine Berni sold 18,160 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.71 ($0.10M total) on 2026-06-15.

Original reporting
SEC EDGAR · Silverstein Christine Berni
Published Jun 15, 2026, 11:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
low confidence
Mentioned
$ABEO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on director ownership reduction via an open-market sale; it may slightly influence sentiment but does not change fundamentals on its own.

02

Market read

Traders may monitor for follow-on insider activity or other catalysts, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing lacks context on motivations, tax planning, or pre-scheduled sales; traders should avoid over-interpreting.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-15 (same day as transaction date).

Background

The article is an SEC Form 4 insider transaction disclosure for ABEONA THERAPEUTICS INC. (ABEO).

Company-level read

Ticker impact

$ABEONeutralLow confidence
Context

SEC Form 4 shows director Silverstein Christine Berni sold 18,160 ABEO shares in an open-market transaction on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other news.

Evidence & confidence

The filing discloses a routine insider sale (no 10b5-1 plan stated) but provides no new operational, regulatory, or financial information.

Market effects

Minimal; single-company insider sale without accompanying company-specific developments.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or liquidity needs and does not necessarily reflect bearish views on ABEO’s prospects.

Key entities

  • ABEO

    Abeona Therapeutics Inc., the company whose shares were sold by a director.

  • Silverstein Christine Berni

    Director who sold 18,160 shares on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.